News | September 24, 2025
Glenmark signs cancer drug licensing deal with Hengrui Pharma for $18 million upfront payment
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
Merck opens first climate-neutral manufacturing facility in Ireland
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
IND application for EB-003 expected in early 2026
Lenalidomide Capsules are indicated for the treatment of adult patients with Multiple myeloma
Subscribe To Our Newsletter & Stay Updated
